Docetaxel-based chemotherapy is currently the standard treatment for metastatic castration-resistant prostate cancer (CRPC) . Two large randomized studies demonstrated that this treatment prolongs survival and also improves time-to-disease progression, pain control and prostate-specific antigen (PSA) response, as compared with mitoxantrone and prednisone [1, 2] . However, patients eventually experience cancer progression within several months and there is currently no established standard treatment after failure of front-line docetaxel-based chemotherapy. Many data indicate that CRPC continues to depend on androgen-receptor signaling even after failure of docetaxel-based chemotherapy [3, 4] . Evidence has also been provided that combining an estrogen-containing drug, estramustine, with chemotherapy may improve overall survival in patients with CRPC [5] . Diethylstilbestrol (DES) is a synthetic ethynil estrogen often used in CRPC as salvage therapy after several hormone manipulations [6] . The activity of DES in patients exhibiting progression after docetaxel-based chemotherapy has not previously been reported. We carried out an analysis to evaluate DES as salvage therapy after first-line docetaxel-based chemotherapy in patients with progressive CRPC. Twenty patients (median age 65.7 years) were treated with DES, given orally at an initial dose of 1 mg daily. None of these patients had received DES before docetaxel. The median duration of prior sensitivity to androgen deprivation therapy was 23 months (range 5-95 months). The median baseline serum PSA value was 45 ng/ml (range 4-680). A PSA response as defined as a PSA decline ‡30% and ‡50% was observed in five (25%) and three (15%) patients, respectively. Among the two patients who had progressive disease while receiving docetaxel, one had a 67% decline in serum PSA. Median progression-free survival was 3.7 months [95% confidence interval (CI) 2.7-4.7 months] and median overall survival was 20.7 months (95% CI 13.4-28.0 months). The cause of DES discontinuation was progressive cancer in all patients. Ten patients have received a preventive anticoagulation by low-dose aspirin. DES was well tolerated overall and only one thromboembolic complication was reported.
These results add to the compelling data indicating that CRPC is hormone sensitive in a significant proportion of cases, even when pretreated with docetaxel-based chemotherapy. Since there is no standard of care when progression occurs after docetaxel-based chemotherapy in patients with CRPC, DES appears as a reasonable option worth considering in this setting. 
